Brokers Issue Forecasts for Aktis Oncology FY2025 Earnings

Aktis Oncology (NASDAQ:AKTS) – HC Wainwright issued their FY2025 EPS estimates for shares of Aktis Oncology in a research note issued on Monday, March 9th. HC Wainwright analyst R. Burns forecasts that the technology company will post earnings of ($2.39) per share for the year. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q4 2025 earnings at ($1.00) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($3.71) EPS.

AKTS has been the subject of several other research reports. Bank of America assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target for the company. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Leerink Partners assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price for the company. Finally, TD Cowen initiated coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $31.25.

Aktis Oncology Price Performance

Shares of AKTS stock opened at $18.98 on Wednesday. Aktis Oncology has a 12 month low of $16.80 and a 12 month high of $29.16. The firm’s 50 day simple moving average is $19.76.

Insider Activity

In related news, Director Ecor1 Capital, Llc acquired 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the completion of the transaction, the director directly owned 4,348,658 shares in the company, valued at $78,275,844. This trade represents a 104.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vida Ventures Ii, Llc purchased 835,000 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the transaction, the insider owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. This represents a 17.26% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 6,117,776 shares of company stock valued at $110,119,968.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.